Developer docs
API playgroundTry for free, no card

Search company profiles

Medaysis

Full company profile

uuid000vope

Namestring
Medaysis
Legal namestring
Medaysis
Websiteurl
medaysis.com
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Medaysis is a privately held biotechnology firm that develops, manufactures, and distributes antibodies and detection reagents for anatomic and molecular pathology research. Its catalog spans more than 1,151 primary antibodies, 47 indirect immunofluorescence products, 22 PCR mutation detection kits, 11 ancillary reagents, and IHC detection kits, covering biomarkers for cancer (e.g., BRAF V600E, PRAME for melanoma), neuropathology (H3K27M, IDH1 R132H, ATRX), and infectious disease applications across multiple tissue types. The company's differentiated technical asset is CloDiA™ PCR, a proprietary ultra-sensitive mutation detection technology designed to measure mutant genes at lower levels than conventional PCR methods, supporting earlier cancer detection and improved prognoses.

The company operates a direct-to-customer, self-serve e-commerce model through its own storefront at medaysis.com, with no disclosed third-party distribution or reseller network. Products are priced on a per-unit, pay-as-you-go basis, with most antibodies ranging from approximately $211 to $843 depending on clone and format (standard concentrate vs. Ready-to-Use). Customers are primarily academic and commercial life science researchers in pathology and molecular biology, served by a team of fewer than 10 employees from a single headquarters in Reno, Nevada. Geographic reach is explicitly U.S.-domestic, and there is no disclosed institutional capital, parent company, partnerships, or named enterprise customers.

The business is therefore best characterized as a small, founder/owner-operated specialty reagent vendor monetizing a deep catalog of validated antibodies plus a proprietary PCR mutation-detection platform, with a self-serve commercial motion and limited evidence of partnership, channel, or geographic expansion beyond the U.S. market.

Short descriptiontext

Medaysis is a small U.S.-based biotech that develops and sells validated primary antibodies, IHC detection kits, and proprietary CloDiA™ PCR mutation detection reagents directly to academic and commercial life science researchers via its e-commerce storefront.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLivermore, United States
HQ citystring
Livermore
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
research antibodies, IHC detection kits, PCR mutation detection, anatomic pathology reagents, molecular pathology products
Industry3 codes
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAHAAAM
IVD Reagents, Assay Kits & Consumables (Non-instrument)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Anatomic and Molecular Pathology Reagents
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Antibody and Reagent Product Sales
TypeOne Time License
Description

Medaysis generates revenue through the sale of research antibodies, detection kits, and ancillary reagents for anatomic and molecular pathology. Products are sold directly through their e-commerce platform with pricing ranging from approximately $197 to $856 depending on the product type and format.

medaysis.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales
Pricing details4 tiers
1Standard Primary Antibodies - Mouse Monoclonal
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Price range approximately $211 to $691 depending on specific antibody clone and format.

medaysis.com
2Rabbit Monoclonal Antibodies
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Price range approximately $236 to $843 depending on specific antibody clone.

medaysis.com
3Rabbit Polyclonal Antibodies
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Price range approximately $289 to $743 depending on specific product.

medaysis.com
4Ready-to-Use (RTU) Formats
ModelUnit PricingBilling cadencePay-as-you-go
Notes

RTU formats available for many antibodies, typically priced at premium compared to standard concentrate formats.

medaysis.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Medaysis develops, manufactures, and sells research-grade antibodies and detection reagents for anatomic and molecular pathology. Its product portfolio includes primary antibodies (1,151+ products), IHC detection kits, indirect immunofluorescence reagents, PCR mutation detection kits built on its proprietary CloDiA™ PCR technology, and ancillary reagents. Products are sold directly through the company's e-commerce website to life science researchers working in cancer, neuroscience, and infectious disease applications.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Medaysis offers a comprehensive portfolio of antibodies and detection reagents for anatomic and molecular pathology research. The product line centers on Primary Antibodies (1,151+ products), supported by IHC Detection reagents, Indirect Immunofluorescence products (47 items), PCR Mutation Detection kits featuring the proprietary CloDiA™ PCR ultra-sensitive technology, and Ancillaries (11 products). The company focuses on cancer biomarkers, neuroscience, and infectious disease research applications, with products available for various tissue types including neuropathology, dermatopathology, gastrointestinal pathology, and hematopathology.

Product and service5 records
1Primary Antibodies
CategoryPrimary Antibodies
Description

Comprehensive catalog of over 1,151 primary antibodies for research use in immunohistochemistry (IHC), covering cancer biomarkers, neuroscience targets, and infectious disease markers across multiple tissue types and clonality formats (mouse monoclonal, rabbit monoclonal, rabbit polyclonal).

2IHC Detection Kits
3Indirect Immunofluorescence Reagents
4PCR Mutation Detection Kits (CloDiA™)
5Ancillaries
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cell Signaling Technology is a leading US-based provider of validated antibodies and reagents for western blot, IHC, IF, flow cytometry, and other applications, with a deep catalog of cancer and neuroscience targets. It is the most direct comparable to Medaysis given overlapping applications (IHC, IF), validated antibody content, and a similar focus on research-use pathology reagents.

2Santa Cruz Biotechnology
TypeDirect peer
Description

Santa Cruz Biotechnology supplies a broad catalog of monoclonal and polyclonal antibodies for research applications including IHC, Western blot, and immunofluorescence. It competes with Medaysis for the same researcher buyer purchasing primary antibodies and detection reagents through online catalogs.

TypeDirect peer
Description

Abcam is one of the largest global suppliers of research-grade antibodies and immunoassay reagents, serving academic and commercial researchers across cancer, neuroscience, and infectious disease. Overlap with Medaysis is direct in primary antibodies, IHC and ICC/IF reagents, and the same self-serve/direct-ship e-commerce buying motion used by researchers.

4MilliporeSigma (Sigma-Aldrich)
TypeBroad incumbent
Description

MilliporeSigma distributes a very large catalog of antibodies, reagents, and biochemicals used in IHC, IF, and molecular pathology research. It is comparable to Medaysis as a one-stop reagents supplier but operates at far greater global scale and breadth.

TypeBroad incumbent
Description

Thermo Fisher's Invitrogen antibody portfolio (including Thermo Scientific and Lab Vision IHC brands) is a broad incumbent offering primary antibodies, IHC detection, and ancillary reagents used in anatomic pathology. It competes with Medaysis across most of its catalog but at much larger scale and with global distribution.

TypeDirect peer
Description

Novus Biologicals supplies a large catalog of antibodies, kits, and reagents with a strong focus on IHC and neuroscience applications. It is a direct peer given shared application areas in IHC/IF, broad SKU breadth, and similar online-purchase, researcher-buyer GTM.

TypeEmerging player
Description

GenScript offers custom antibody services and an off-the-shelf antibody catalog, including reagents used in cancer and infectious disease research. It overlaps with Medaysis in primary antibody products and develops proprietary research tools like the CloDiA-style platforms.

TypeDirect peer
Description

BioLegend provides antibodies and reagents for immunology, cancer, and neuroscience research, including flow cytometry and IHC-grade antibodies. It is comparable to Medaysis in offering validated antibodies across pathology-relevant applications and marketing directly to life science researchers.

TypeDirect peer
Description

Atlas Antibodies specializes in IHC-validated antibodies, including the Triple A Polyclonals and PrecisA Monoclonals lines for human protein atlas applications, with strong neuropathology and tissue-specific content. It is a direct peer given the shared focus on IHC-grade antibodies and neuropathology biomarkers.

10Bethyl Laboratories
TypeDirect peer
Description

Bethyl Laboratories manufactures and validates polyclonal and monoclonal antibodies for academic and commercial research, with strong offerings in IHC, ChIP, and Western blot. It is comparable to Medaysis as a focused, antibody-centric tools vendor selling validated reagents directly to research customers.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Medaysis

Anatomic and Molecular Pathology Reagentsmedaysis.com

Medaysis is a small U.S.-based biotech that develops and sells validated primary antibodies, IHC detection kits, and proprietary CloDiA™ PCR mutation detection reagents directly to academic and commercial life science researchers via its e-commerce storefront.

What Medaysis does

Medaysis is a privately held biotechnology firm that develops, manufactures, and distributes antibodies and detection reagents for anatomic and molecular pathology research. Its catalog spans more than 1,151 primary antibodies, 47 indirect immunofluorescence products, 22 PCR mutation detection kits, 11 ancillary reagents, and IHC detection kits, covering biomarkers for cancer (e.g., BRAF V600E, PRAME for melanoma), neuropathology (H3K27M, IDH1 R132H, ATRX), and infectious disease applications across multiple tissue types. The company's differentiated technical asset is CloDiA™ PCR, a proprietary ultra-sensitive mutation detection technology designed to measure mutant genes at lower levels than conventional PCR methods, supporting earlier cancer detection and improved prognoses.

The company operates a direct-to-customer, self-serve e-commerce model through its own storefront at medaysis.com, with no disclosed third-party distribution or reseller network. Products are priced on a per-unit, pay-as-you-go basis, with most antibodies ranging from approximately $211 to $843 depending on clone and format (standard concentrate vs. Ready-to-Use). Customers are primarily academic and commercial life science researchers in pathology and molecular biology, served by a team of fewer than 10 employees from a single headquarters in Reno, Nevada. Geographic reach is explicitly U.S.-domestic, and there is no disclosed institutional capital, parent company, partnerships, or named enterprise customers.

The business is therefore best characterized as a small, founder/owner-operated specialty reagent vendor monetizing a deep catalog of validated antibodies plus a proprietary PCR mutation-detection platform, with a self-serve commercial motion and limited evidence of partnership, channel, or geographic expansion beyond the U.S. market.

Medaysis firmographics

Firmographics
Name
Medaysis
Legal name
Medaysis
Website
https://medaysis.com
Company type
Private
Operating status
Operating
Headcount range
1–10 employees
Short description
Medaysis is a small U.S.-based biotech that develops and sells validated primary antibodies, IHC detection kits, and proprietary CloDiA™ PCR mutation detection reagents directly to academic and commercial life science researchers via its e-commerce storefront.
Ownership category
akta.pro rank

Medaysis industry classification

Industry
Product category
Anatomic and Molecular Pathology Reagents
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAHAAAM
IVD Reagents, Assay Kits & Consumables (Non-instrument)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • Research antibodies
  • IHC detection kits
  • PCR mutation detection
  • Anatomic pathology reagents
  • Molecular pathology products

Where Medaysis is headquartered

Location

Headquarters

HQ city
Livermore
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Medaysis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales

Revenue model

  1. Antibody and Reagent Product Sales: Medaysis generates revenue through the sale of research antibodies, detection kits, and ancillary reagents for anatomic and molecular pathology. Products are sold directly through their e-commerce platform with pricing ranging from approximately $197 to $856 depending on the product type and format.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goStandard Primary Antibodies - Mouse Monoclonal
Unit PricingPay-as-you-goRabbit Monoclonal Antibodies
Unit PricingPay-as-you-goRabbit Polyclonal Antibodies
Unit PricingPay-as-you-goReady-to-Use (RTU) Formats

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Medaysis product offering

Product offering

Core offering

Medaysis develops, manufactures, and sells research-grade antibodies and detection reagents for anatomic and molecular pathology. Its product portfolio includes primary antibodies (1,151+ products), IHC detection kits, indirect immunofluorescence reagents, PCR mutation detection kits built on its proprietary CloDiA™ PCR technology, and ancillary reagents. Products are sold directly through the company's e-commerce website to life science researchers working in cancer, neuroscience, and infectious disease applications.

Product overview

Medaysis offers a comprehensive portfolio of antibodies and detection reagents for anatomic and molecular pathology research. The product line centers on Primary Antibodies (1,151+ products), supported by IHC Detection reagents, Indirect Immunofluorescence products (47 items), PCR Mutation Detection kits featuring the proprietary CloDiA™ PCR ultra-sensitive technology, and Ancillaries (11 products). The company focuses on cancer biomarkers, neuroscience, and infectious disease research applications, with products available for various tissue types including neuropathology, dermatopathology, gastrointestinal pathology, and hematopathology.

Differentiator

Problem solved

Functional benefit

Products and services

  • Primary Antibodies Comprehensive catalog of over 1,151 primary antibodies for research use in immunohistochemistry (IHC), covering cancer biomarkers, neuroscience targets, and infectious disease markers across multiple tissue types and clonality formats (mouse monoclonal, rabbit monoclonal, rabbit polyclonal).
  • IHC Detection Kits
  • Indirect Immunofluorescence Reagents
  • PCR Mutation Detection Kits (CloDiA™)
  • Ancillaries

Companies that use Medaysis

Customer profile

Segments1 record

Ideal customer profiles1 record

Medaysis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Medaysis partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves5 records

Expansion highlights3 records

Medaysis competitors and assessment

Company assessment

Direct peers

  • Cell Signaling Technology: Cell Signaling Technology is a leading US-based provider of validated antibodies and reagents for western blot, IHC, IF, flow cytometry, and other applications, with a deep catalog of cancer and neuroscience targets. It is the most direct comparable to Medaysis given overlapping applications (IHC, IF), validated antibody content, and a similar focus on research-use pathology reagents.
  • Santa Cruz Biotechnology: Santa Cruz Biotechnology supplies a broad catalog of monoclonal and polyclonal antibodies for research applications including IHC, Western blot, and immunofluorescence. It competes with Medaysis for the same researcher buyer purchasing primary antibodies and detection reagents through online catalogs.
  • Abcam (Danaher): Abcam is one of the largest global suppliers of research-grade antibodies and immunoassay reagents, serving academic and commercial researchers across cancer, neuroscience, and infectious disease. Overlap with Medaysis is direct in primary antibodies, IHC and ICC/IF reagents, and the same self-serve/direct-ship e-commerce buying motion used by researchers.
  • Novus Biologicals (Bio-Techne): Novus Biologicals supplies a large catalog of antibodies, kits, and reagents with a strong focus on IHC and neuroscience applications. It is a direct peer given shared application areas in IHC/IF, broad SKU breadth, and similar online-purchase, researcher-buyer GTM.
  • BioLegend (Bio-Techne): BioLegend provides antibodies and reagents for immunology, cancer, and neuroscience research, including flow cytometry and IHC-grade antibodies. It is comparable to Medaysis in offering validated antibodies across pathology-relevant applications and marketing directly to life science researchers.
  • Atlas Antibodies: Atlas Antibodies specializes in IHC-validated antibodies, including the Triple A Polyclonals and PrecisA Monoclonals lines for human protein atlas applications, with strong neuropathology and tissue-specific content. It is a direct peer given the shared focus on IHC-grade antibodies and neuropathology biomarkers.
  • Bethyl Laboratories: Bethyl Laboratories manufactures and validates polyclonal and monoclonal antibodies for academic and commercial research, with strong offerings in IHC, ChIP, and Western blot. It is comparable to Medaysis as a focused, antibody-centric tools vendor selling validated reagents directly to research customers.

Broad incumbents

  • MilliporeSigma (Sigma-Aldrich): MilliporeSigma distributes a very large catalog of antibodies, reagents, and biochemicals used in IHC, IF, and molecular pathology research. It is comparable to Medaysis as a one-stop reagents supplier but operates at far greater global scale and breadth.
  • Thermo Fisher Scientific (Invitrogen Antibodies): Thermo Fisher's Invitrogen antibody portfolio (including Thermo Scientific and Lab Vision IHC brands) is a broad incumbent offering primary antibodies, IHC detection, and ancillary reagents used in anatomic pathology. It competes with Medaysis across most of its catalog but at much larger scale and with global distribution.

Emerging players

  • GenScript: GenScript offers custom antibody services and an off-the-shelf antibody catalog, including reagents used in cancer and infectious disease research. It overlaps with Medaysis in primary antibody products and develops proprietary research tools like the CloDiA-style platforms.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Medaysis social profiles

Digital presence

Medaysis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medaysis leadership team

Management profile

Number of profiles

Medaysis funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medaysis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medaysis

What does Medaysis do?

Medaysis develops, manufactures, and sells research-grade antibodies and detection reagents for anatomic and molecular pathology. Its product portfolio includes primary antibodies (1,151+ products), IHC detection kits, indirect immunofluorescence reagents, PCR mutation detection kits built on its proprietary CloDiA™ PCR technology, and ancillary reagents. Products are sold directly through the company's e-commerce website to life science researchers working in cancer, neuroscience, and infectious disease applications.

Is Medaysis a public or private company?

Medaysis is a private company. It is classified as unknown and is currently operating.

When was Medaysis founded?

Medaysis was founded in -1. It employs 1 to 10 people.

Where is Medaysis based?

Medaysis is headquartered in Livermore, United States, in the North America region.

How does Medaysis make money?

One revenue line is on record: antibody and Reagent Product Sales.

Who are Medaysis's main competitors?

Direct peers on record are Cell Signaling Technology, Santa Cruz Biotechnology, Abcam (Danaher), Novus Biologicals (Bio-Techne), BioLegend (Bio-Techne), Atlas Antibodies and Bethyl Laboratories. Broad incumbents are MilliporeSigma (Sigma-Aldrich) and Thermo Fisher Scientific (Invitrogen Antibodies). GenScript is listed as an emerging player.

Does Medaysis have an API?

No public API is recorded for Medaysis.

What industry is Medaysis in?

Medaysis's product category is Anatomic and Molecular Pathology Reagents. Its primary akta.pro industry code is HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes), with a secondary code of HLAAAMAL, Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales